Compare Fidelity National Information Servcs Inc (FIS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Mesoblast Limited — how do they compare? Fidelity National Information Servcs Inc trades at $42.11 (market cap $21.24B), while Mesoblast Limited trades at $18.78 (market cap $2.31B). The key difference: Fidelity National Information Servcs Inc is far larger — about 9.2× Mesoblast Limited's market cap, and Fidelity National Information Servcs Inc pays a 4.09% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| FIS | MESO | |
|---|---|---|
Market Cap | $21.24B | $2.31B |
Sector | Technology | Technology |
52-Week High | $81.94 | $20.96 |
52-Week Low | $37.72 | $11.35 |
Enterprise Value | $41.63B | $2.32B |
Dividend Yield | 4.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.02, up 3.54% today, with a bearish technical signal but strong analyst support. The company shows improving fundamentals with Q1 2026 EPS beating expectations and a consensus price target of $52.57. Recent news highlights innovation in AI and cloud banking, though cash flow trends and debt levels warrant monitoring.
The outlook is cautiously optimistic with potential upside from earnings growth and strategic initiatives, balanced by risks from competitive pressures and financial leverage. Investor sentiment is positive driven by analyst buy ratings and recent business wins, but volatility may persist near-term.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
